Material Insights · Understanding the Material World

CRISPR gene editing: Materials

Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is

Uses

as of 2026-11-11. No amounts are given: the inputs are small amounts of specialised chemicals, and the dual-use rule keeps production detail out. Criticality is the writer's judgement.

Critical materials

The materials whose supply could hold it back

  • No raw material is likely to hold gene editing back: enzymes and short RNAs are made in small amounts.
  • The constraints are policy ones: medicines need approval by regulators such as the MHRA and FDA [3, 4], and WHO's 2021 recommendations call for registries of human genome editing research and a way to report concerns [5].
  • Editing embryos so that changes pass to children carries risks that WHO singles out [5].

as of 2026-11-11

Sources

  1. A Tool for Genome Editing: Scientific Background on the Nobel Prize in Chemistry 2020 Royal Swedish Academy of Sciences, 2020
  2. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease US Food and Drug Administration, 2023
  3. MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia Medicines and Healthcare products Regulatory Agency (GOV.UK), 2023
  4. WHO issues new recommendations on human genome editing for the advancement of public health World Health Organization, 2021